Mr Lund has an MA in Economics from the Norwegian School of Economics & Business Administration (NHH), Norway, from 1987 and an MBA from INSEAD, France, from 1991. From 2014 to 2015 Mr Lund was a member of the Board of Directors of Novo Nordisk A/S. Mr Lund was elected to the Board of Novo Nordisk A/S again in March 2017. His term as a board member expires in March 2018. In March 2017, the Board of Directors of Novo Nordisk A/S assessed that Mr Lund is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen. Mr Lund became a member of the Audit Committee at Novo Nordisk A/S in March 2017. In March 2017, the Board of Directors of Novo Nordisk A/S designated Mr Lund as financial expert as defined by the US Securities and Exchange Commission (SEC) and assessed that Mr Lund qualifies as independent pursuant to the US Securities Exchange Act. In addition, the Board of Directors of Novo Nordisk A/S assessed that Mr Lund has competences in accounting and auditing as required by the Danish Act on Approved Auditors and Audit Firms. Mr Lund became a member of the Nomination Committee at Novo Nordisk A/S in March 2017.

 Pharmaceuticals